Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: G.P. who wrote (4019)	5/12/2000 12:47:00 PM
From: Hogger	Read Replies (1) \| Respond to of 4028

Here's the entire text of a an article about a much better subject:: doubletwist.com Antisense Making Itself: CytoGenix's Plasmid Approach When is antisense not antisense? CytoGenix(Houston, TX), which recently changed its name from Cryogenic Solutions, is trying to avoid the use of chemical getting the cell to manufacture its own antisense compounds. Introduced to the cell via vector, the instructions for constructing an antisense oligonucleotide sit in the cytosol, happily churning out whatever antisense sequence it isprogrammed to make. The research is still at a very early stage, says company spokesperson Dell Gibson, with "excellent" tissue culture results, but animal studies are just beginning at the Southwest Biomedical Foundation in Houston. It sounds a little like gene therapy-meets-antisense, but Gibson is quick to stress the fact that the "cassette" containing instructions for the antisense oligo does not incorporate into the cellular genome. Rather, it sits in a plasmid construct. "We're not trying to change the operating system. We're just deleting files," he says. In fact, this is not a new approach. Much of the work done in plant engineering is accomplished through this kind of antisense, including the creation of the first genetically engineered food approved for sale in the US, Calgene's "Flavr Savr" tomato. Calgene, now part of Monsanto Co. (St. Louis, MO) introduced a plasmid into tomato seeds that inhibited the function of a gene responsible for making the plant rot. In humans, however, this approach is "a tough, tough way to go," suggests GeneTools' Dr. James Summerton. Getting enough plasmid into enough cells to cause an effect is very difficult, he asserts. "If you're trying to cure a genetic illness, it might be feasible--if you introduce it early, ideally just before the egg is fertilized"--in other words, using the technology the way it is used in plants.